BioSpace News Archive

The FDA ordered Avidity Biosciences to halt clinical trial enrollment after a patient suffered a “serious adverse event” testing the company’s candidate drug for myotonic dystrophy type 1.

During an R&D presentation Tuesday, Transgene executives and oncology experts highlighted promising therapeutic progress in its programs - focusing on its developmental cancer vaccines.

Colossal started the “de-extinction” of the thylacine, commonly known as the Tasmania tiger. Now with a $30 million investment, this technology is gaining more traction.

The U.S. Equal Employment Opportunity Commission filed a lawsuit Monday against Eli Lilly and Co. alleging the company refused to hire older workers for sales representative positions.

Shares of Exicure, Inc. are falling after the company announced a strategic initiative that casts doubts on its future developmental programs.

Sanofi has inked a licensing deal with Scribe Therapeutics to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology.

FUJIFILM Dyosynth Biotechnologies, Taysha Gene Therapies, Veravas highlight innovation stemming from the Lone Star state. BioSpace takes a deep dive into these and other Texas innovators.

The FDA has granted a rolling review to CRISPR Therapeutics and Vertex’s exa-cel, a potential one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia.

RegeneRx Biopharmaceuticals, Inc. is reporting today that its U.S. joint venture (JV) partner and licensee, HLB Therapeutics (HLBT), has announced that it submitted a protocol for its second phase 3 clinical trial (SEER-2) to the U.S. FDA on September 26th, evaluating RGN-259 as a treatment for neurotrophic keratopathy (NK).

The latest market analysis report published by Reports and Data, titled ‘Global Diabetic Neuropathy Market – Forecast to 2030,’ thoroughly examines the Diabetic Neuropathy industry to provide essential data & information for the targeted readers. The report consists of quantitative and qualitative research on the market performed by our market experts.